Form 4: Interpace Biosciences Investor 1315 Capital II, L.P. Exchanges Series B Preferred Stock for Series C

1315 Capital II, L.P., a 10% owner of Interpace Biosciences, exchanged its Series B Convertible Preferred Stock for newly created Series C Convertible Preferred Stock on October 11, 2024.

Summary

• On October 11, 2024, 1315 Capital II, L.P., a significant shareholder of Interpace Biosciences, exchanged 19,000 shares of Series B Convertible Preferred Stock for 19,000 newly issued shares of Series C Convertible Preferred Stock.
• The Series B Preferred Shares were convertible into common stock at a conversion price of $6.00 per share.
• The Series C Preferred Shares are convertible into common stock at an initial conversion price of $2.02 per share.
• 1315 Capital Management II, LLC, as the general partner of 1315 Capital II, L.P., may be deemed to have voting and investment power over the securities.
• Both the Series B and Series C Preferred Shares have no expiration date.

Sentiment

Score: 6

Explanation: The document describes a routine transaction. It's neither particularly positive nor negative from an investment perspective.

Industry Context

This transaction reflects ongoing investment and adjustments in the capital structure of Interpace Biosciences, which is common in the biotechnology industry.

Key Dates

Keywords

Interpace Biosciences, 1315 Capital II, L.P., Series C Convertible Preferred Stock, Series B Convertible Preferred Stock, Conversion, Share Exchange, Beneficial Ownership